Eton Pharmaceuticals Inc - Company Profile
Powered by 
All the sales intelligence you need on Eton Pharmaceuticals Inc in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Eton Pharmaceuticals Inc fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Eton Pharmaceuticals Inc.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Eton Pharmaceuticals Inc (Eton Pharmaceuticals) is a pharmaceutical company. It focuses on the development and commercialization of pharmaceutical products. The company’s pipeline products include ET-600 and ET-800 which treats endocrinology; ET-700 for metabolic genetics. Eton Pharmaceuticals also offers Alkindi Sprinkle, Carglumic Acid, Galzin, Betaine Anhydrous, Increlex, Nitisinone and others. The company provides products in various therapeutic areas. It develops its products in multiple dosage forms including liquid formulations, sterile injectables, oral liquids and others. Eton Pharmaceuticals is headquartered in Deer Park, Illinois, the US.
Headquarters
United States of America
Address
#235, 21925 W Field Pkwy, Deer Park, Illinois, 60010-7278
Website
etonpharma.com
Telephone
1 847 7877361
No of Employees
44
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
ETON (NASD)
Revenue (2024)
$80.0M
104.9%
(2024 vs 2023)
EPS
XYZ
Net Income (2024)
XYZ
-20.4%
(2024 vs 2023)
Market Cap*
$1.5B
Net Profit Margin (2024)
XYZ
41.3%
(2024 vs 2023)
* As of and is in US$
Eton Pharmaceuticals Inc premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Galzin | Alkindi Sprinkle |
| Increlex | Galzin |
| Khindivi | Increlex |
| XYZ | XYZ |
| XYZ | XYZ |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2025 | Acquisitions/Mergers/Takeovers | In January, the company acquired Galzin (zinc acetate). |
| 2024 | Acquisitions/Mergers/Takeovers | In December, the company purchased Increlex (mecasermin injection) from Ipsen SA. |
| 2024 | Acquisitions/Mergers/Takeovers | In November, the company acquired the US rights to Amglidia to treat neonatal diabetes mellitus from AMMTeK. |
Competitor Comparison
| Key Parameters | Eton Pharmaceuticals Inc | BioXcel Therapeutics Inc | Innovus Pharmaceuticals Inc | Biostax Corp |
|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United States of America | United States of America |
| City | Deer Park | New Haven | San Diego | Winter Park |
| State/Province | Illinois | Connecticut | California | Florida |
| No. of Employees | 44 | 29 | 1 | - |
| Entity Type | Public | Public | Private | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Norbert G. Riedel, PhD | Chairman | Executive Board | 2018 | 67 |
| Sean E. Brynjelsen | Chief Executive Officer; Director; President | Executive Board | 2017 | 53 |
| Judith M. Matthews | Chief Financial Officer; Executive Vice President - Accounting and Finance | Senior Management | 2026 | - |
| Scott Grossenbach | Senior Vice President - Sales Operations | Senior Management | - | - |
| Danka Radosavljevic | Executive Vice President - Operations | Senior Management | - | - |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer